Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
Evelina Miele1, Gian Paolo Spinelli1, Ermanno Miele2, Federica Tomao1, Silverio Tomao11Department of Experimental Medicine, University of Rome “Sapienza”, Rome, Italy; 2Biomedical Engineering, University of Rome Tor Vergata, Rome, ItalyAbstract: Breast cancer is the most...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2009
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/bbcf6ea63fcb4cb1aea26ac70bf710aa |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:bbcf6ea63fcb4cb1aea26ac70bf710aa |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:bbcf6ea63fcb4cb1aea26ac70bf710aa2021-12-02T02:38:18ZAlbumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer1176-91141178-2013https://doaj.org/article/bbcf6ea63fcb4cb1aea26ac70bf710aa2009-04-01T00:00:00Zhttp://www.dovepress.com/albumin-bound-formulation-of-paclitaxel-abraxanereg-abi-007-in-the-tre-a3077https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Evelina Miele1, Gian Paolo Spinelli1, Ermanno Miele2, Federica Tomao1, Silverio Tomao11Department of Experimental Medicine, University of Rome “Sapienza”, Rome, Italy; 2Biomedical Engineering, University of Rome Tor Vergata, Rome, ItalyAbstract: Breast cancer is the most common type of malignancy diagnosed in women. In the metastatic setting this disease is still uncurable. Taxanes represent an important class of antitumor agents which have proven to be fundamental in the treatment of advanced and early-stage breast cancer, but the clinical advances of taxanes have been limited by their highly hydrophobic molecular status. To overcome this poor water solubility, lipid-based solvents have been used as a vehicle, and new systemic formulations have been developed, mostly for paclitaxel, which are Cremophor-free and increase the circulation time of the drug. ABI-007 is a novel, albumin-bound, 130-nm particle formulation of paclitaxel, free from any kind of solvent. It has been demonstrated to be superior to an equitoxic dose of standard paclitaxel with a significantly lower incidence of toxicities in a large, international, randomized phase III trial. The availability of new drugs, such as Abraxane®, in association with other traditional and non-traditional drugs (new antineoplastic agents and targeted molecules), will give the oncologist many different effective treatment options for patients in this setting.Keywords: paclitaxel, Abraxane, breast cancer, nanotechnology Evelina MieleGian Paolo SpinelliErmanno MieleFederica TomaoSilverio TomaoDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2009, Iss default, Pp 99-105 (2009) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 Evelina Miele Gian Paolo Spinelli Ermanno Miele Federica Tomao Silverio Tomao Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer |
| description |
Evelina Miele1, Gian Paolo Spinelli1, Ermanno Miele2, Federica Tomao1, Silverio Tomao11Department of Experimental Medicine, University of Rome “Sapienza”, Rome, Italy; 2Biomedical Engineering, University of Rome Tor Vergata, Rome, ItalyAbstract: Breast cancer is the most common type of malignancy diagnosed in women. In the metastatic setting this disease is still uncurable. Taxanes represent an important class of antitumor agents which have proven to be fundamental in the treatment of advanced and early-stage breast cancer, but the clinical advances of taxanes have been limited by their highly hydrophobic molecular status. To overcome this poor water solubility, lipid-based solvents have been used as a vehicle, and new systemic formulations have been developed, mostly for paclitaxel, which are Cremophor-free and increase the circulation time of the drug. ABI-007 is a novel, albumin-bound, 130-nm particle formulation of paclitaxel, free from any kind of solvent. It has been demonstrated to be superior to an equitoxic dose of standard paclitaxel with a significantly lower incidence of toxicities in a large, international, randomized phase III trial. The availability of new drugs, such as Abraxane®, in association with other traditional and non-traditional drugs (new antineoplastic agents and targeted molecules), will give the oncologist many different effective treatment options for patients in this setting.Keywords: paclitaxel, Abraxane, breast cancer, nanotechnology |
| format |
article |
| author |
Evelina Miele Gian Paolo Spinelli Ermanno Miele Federica Tomao Silverio Tomao |
| author_facet |
Evelina Miele Gian Paolo Spinelli Ermanno Miele Federica Tomao Silverio Tomao |
| author_sort |
Evelina Miele |
| title |
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer |
| title_short |
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer |
| title_full |
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer |
| title_fullStr |
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer |
| title_full_unstemmed |
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer |
| title_sort |
albumin-bound formulation of paclitaxel (abraxane® abi-007) in the treatment of breast cancer |
| publisher |
Dove Medical Press |
| publishDate |
2009 |
| url |
https://doaj.org/article/bbcf6ea63fcb4cb1aea26ac70bf710aa |
| work_keys_str_mv |
AT evelinamiele albuminboundformulationofpaclitaxelabraxaneampregabi007inthetreatmentofbreastcancer AT gianpaolospinelli albuminboundformulationofpaclitaxelabraxaneampregabi007inthetreatmentofbreastcancer AT ermannomiele albuminboundformulationofpaclitaxelabraxaneampregabi007inthetreatmentofbreastcancer AT federicatomao albuminboundformulationofpaclitaxelabraxaneampregabi007inthetreatmentofbreastcancer AT silveriotomao albuminboundformulationofpaclitaxelabraxaneampregabi007inthetreatmentofbreastcancer |
| _version_ |
1718402314456268800 |